The FDA has granted orphan drug designation to namodenoson (CF102) in pancreatic cancer. Orphan drug designation provides Can ...

Jacob E. Berchuck, MD, discussed research behind using a blood-based liquid biopsy in prostate cancer and findings presented ...

During a Case-Based Roundtable® event, Chandler Park, MD, moderated a discussion on how recent trial data and sites of ...

The first patient in a phase 1/2 trial investigating a novel agent for the treatment of non–small cell lung cancer has been ...

The SunRISe-2 trial evaluating TAR-200 combined with cetrelimab vs chemoradiation in muscle-invasive bladder cancer has been ...

The KEYNOTE-689 study evaluating pembrolizumab in this patient population met its primary end point of event-free survival.

Ana Baramidze, MD, PhD, discussed 5-year follow-up results from the EMPOWER-Lung study evaluating cemiplimab vs chemotherapy ...

The FDA has granted VLS-1488 fast track designation in patients with platinum-resistant high-grade serous ovarian cancer.

Jaime Merchan, MD, discusses what the potential clinical implications or takeaways for colleagues are based on findings from ...

Erika P. Hamilton, MD, discusses the patient population with breast cancer enrolled in the TROPION-PanTumor01 trial in ...

The CHRYSALIS-2 study (NCT04077463) evaluated the combination of amivantamab (Rybrevant), an EGFR-MET bispecific antibody, ...

In an interview with Targeted Oncology, Rupesh Kotecha, MD, discussed a machine learning tool designed to predict local ...